Sangamo Therapeutics (NASDAQ:SGMO) Rating Increased to Strong-Buy at ValuEngine

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday, ValuEngine reports.

Several other brokerages have also recently commented on SGMO. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 17th. Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research note on Monday, July 8th. Four investment analysts have rated the stock with a hold rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $13.33.

Shares of NASDAQ SGMO traded down $0.39 during midday trading on Thursday, hitting $11.45. The company had a trading volume of 1,467,447 shares, compared to its average volume of 2,451,676. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.98 and a quick ratio of 3.98. Sangamo Therapeutics has a twelve month low of $6.26 and a twelve month high of $19.25. The firm has a 50-day simple moving average of $11.08. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -16.36 and a beta of 2.93.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.14). Sangamo Therapeutics had a negative net margin of 113.03% and a negative return on equity of 24.67%. The company had revenue of $8.07 million during the quarter, compared to analyst estimates of $27.21 million. Research analysts forecast that Sangamo Therapeutics will post -1.46 earnings per share for the current fiscal year.

In related news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the sale, the chief financial officer now owns 30,512 shares in the company, valued at $305,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of SGMO. Wasatch Advisors Inc. increased its holdings in Sangamo Therapeutics by 26.8% during the 1st quarter. Wasatch Advisors Inc. now owns 6,437,908 shares of the biopharmaceutical company’s stock valued at $61,418,000 after acquiring an additional 1,359,170 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Sangamo Therapeutics by 459.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock valued at $14,224,000 after acquiring an additional 1,017,573 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in Sangamo Therapeutics during the 2nd quarter valued at about $4,450,000. Bailard Inc. increased its holdings in Sangamo Therapeutics by 373.0% during the 1st quarter. Bailard Inc. now owns 156,100 shares of the biopharmaceutical company’s stock valued at $1,489,000 after acquiring an additional 123,100 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Sangamo Therapeutics by 97.4% during the 4th quarter. Two Sigma Advisers LP now owns 203,300 shares of the biopharmaceutical company’s stock valued at $2,334,000 after acquiring an additional 100,300 shares in the last quarter. Hedge funds and other institutional investors own 57.32% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Recommended Story: Cost of Capital

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.